ATE551432T1 - Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege - Google Patents

Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege

Info

Publication number
ATE551432T1
ATE551432T1 AT05762518T AT05762518T ATE551432T1 AT E551432 T1 ATE551432 T1 AT E551432T1 AT 05762518 T AT05762518 T AT 05762518T AT 05762518 T AT05762518 T AT 05762518T AT E551432 T1 ATE551432 T1 AT E551432T1
Authority
AT
Austria
Prior art keywords
depressive disease
manic
genes
expressed differently
disease
Prior art date
Application number
AT05762518T
Other languages
English (en)
Inventor
Huda Akil
Jr William E Bunney
Prabhakara V Choudary
Simon J Evans
Edward G Jones
Jun Li
Juan F Lopez
David M Lyons
Margherita Molnar
Richard M Myers
Alan F Schatzberg
Richard Stein
Robert C Thompson
Hiroaki Tomita
Marquis P Vawter
Stanley J Watson
Cortney A Turner
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE551432T1 publication Critical patent/ATE551432T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05762518T 2004-06-21 2005-06-21 Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege ATE551432T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58199804P 2004-06-21 2004-06-21
US62125204P 2004-10-22 2004-10-22
US66729605P 2005-03-31 2005-03-31
PCT/US2005/022111 WO2006002262A2 (en) 2004-06-21 2005-06-21 Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder

Publications (1)

Publication Number Publication Date
ATE551432T1 true ATE551432T1 (de) 2012-04-15

Family

ID=35782328

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05762518T ATE551432T1 (de) 2004-06-21 2005-06-21 Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege

Country Status (8)

Country Link
US (3) US8415298B2 (de)
EP (2) EP1766077B1 (de)
AT (1) ATE551432T1 (de)
AU (1) AU2005258161B2 (de)
CA (1) CA2571243A1 (de)
DK (2) DK1766077T3 (de)
ES (1) ES2660765T3 (de)
WO (1) WO2006002262A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047727A2 (en) * 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
AU2006315562C1 (en) * 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
US8163475B2 (en) * 2006-05-18 2012-04-24 The Mclean Hospital Corporation Methods for diagnosis and prognosis of psychotic disorders
WO2008124428A1 (en) * 2007-04-03 2008-10-16 Indiana University Research And Technology Corporation Blood biomarkers for mood disorders
US20100248230A1 (en) * 2007-04-14 2010-09-30 Schlaak Joerg Friedrich Novel medical diagnostic method and therapy in the context of interfreon-stimulated genes that induce depression
WO2008144371A1 (en) * 2007-05-16 2008-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for diagnosing suicidal tendencies
WO2009011911A2 (en) * 2007-07-18 2009-01-22 The Johns Hopkins University Methods of detecting prostate cancer
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
WO2009059316A1 (en) * 2007-11-02 2009-05-07 The Board Of Trustees Of The Leland Stanford Junior University Fgf9-related methods for treating anxiety
EP2514840B1 (de) * 2008-01-02 2014-10-22 Suregene Llc Genetische Marker für Geisteskrankheiten, im besonderen im ASTN2 Gen.
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
GB0808834D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
GB0808832D0 (en) * 2008-05-15 2008-06-18 Ge Healthcare Ltd Biomarkers for depression
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
BRPI0914859A2 (pt) * 2008-08-27 2015-11-03 Lundbeck & Co As H método para diagnosticar um distúrbio afetivo, produto de programa de computador, computador, e, método para determinar uma probabilidade de que um indivíduo de teste exiba um sintoma de um distúrbio afetivo
JP5881420B2 (ja) * 2008-11-12 2016-03-09 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 自閉症関連遺伝子マーカー
AU2009313759B2 (en) * 2008-11-14 2016-05-12 The Children's Hospital Of Philadelphia Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201204816D0 (en) * 2012-03-19 2012-05-02 Brainco Biopharma S L Transgenic animal model of mood disorders
US10301615B2 (en) 2013-03-01 2019-05-28 Psychnostics, Llc Genes expressed in mental illness and mood disorders
WO2014159720A1 (en) * 2013-03-13 2014-10-02 The University Of Chicago Methods and compositions for inhibiting glyoxalase 1 (glo1)
US20160209428A1 (en) * 2013-08-21 2016-07-21 The Regents Of The University Of California Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system
WO2015129324A1 (ja) * 2014-02-26 2015-09-03 国立大学法人徳島大学 精神疾患マーカーおよびその用途
CN109022486B (zh) * 2018-09-20 2021-09-07 河北医科大学第二医院 一种癫痫动物模型的构建方法
EP3819387A1 (de) * 2019-11-08 2021-05-12 Alcediag Differentialdiagnose von bipolarer störung und unipolarer depression durch blut-rna-bearbeitungsbiomarker
CN111621525B (zh) * 2020-06-18 2021-04-23 中赛干细胞基因工程有限公司 Stx1b基因在促进人脂肪间充质干细胞生长和分化中的用途
US20230420110A1 (en) * 2020-11-18 2023-12-28 Indiana University Research And Technology Corporation Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders
CN116904578B (zh) * 2023-07-21 2024-03-15 武汉市精神卫生中心 线粒体差异化表达特征基因在制备重度抑郁症诊断剂中的应用
CN120883057A (zh) * 2024-02-29 2025-10-31 百越达析 用于区分抑郁症和双相情感障碍的生物标志物及其用途

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US6187752B1 (en) 1988-03-07 2001-02-13 E.R. Squibb & Sons, Inc. Method for treating schizophrenia employing an ace inhibitor
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
EP0633943A4 (de) 1992-04-03 1997-05-02 Alexander T Young Gentherapy unter verwendung zielgerichteter viraler vektoren.
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
ES2061380B1 (es) 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
DK1921169T3 (da) 1993-11-12 2012-06-04 Phri Properties Inc Hybridiseringssonder til nukleinsyredetektion, universelle stamceller, fremgangsmåder og kits
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
FR2718150B1 (fr) 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US6024734A (en) 1994-03-31 2000-02-15 Brewitt; Barbara A. Treatment methods using homeopathic preparations of growth factors
US20030191061A1 (en) 1994-03-31 2003-10-09 Brewitt Barbara A. Treatment methods using homeopathic preparations of growth factors
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
WO1996041620A1 (en) 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgfr3 as a marker for mesenchymal skeletal progenitor cells
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
CA2240667A1 (en) 1995-12-18 1997-06-26 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
EP0894004B2 (de) * 1996-03-22 2007-02-21 Curis, Inc. Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder isch?mie des zns
US6117890A (en) 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
KR20000057303A (ko) 1996-12-24 2000-09-15 후지야마 아키라 아미노피페라진 유도체의 신규 용도
JP2001520653A (ja) 1997-04-11 2001-10-30 エリ リリー アンド カンパニー 精神分裂病の治療法
EP1014974B1 (de) 1997-05-29 2004-08-11 H. Lundbeck A/S Behandlung der schizophrenie und der psychose
CA2216686A1 (en) 1997-09-24 1999-03-24 Guy A. Rouleau Allelic variants of the phospholipase c-gamma1 gene associated with bipolar disorder
DK1026950T3 (da) 1997-10-27 2006-06-26 Univ California Behandling af skizofreni med ampakiner og neuroleptika
BR9911068A (pt) 1998-05-29 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de distúrbios bipolares
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
AUPP810399A0 (en) 1999-01-11 1999-02-04 Unisearch Limited Catalytic molecules
JP2002539845A (ja) 1999-03-30 2002-11-26 ジェンセット 精神分裂病関連遺伝子、タンパク質およびバイアレリックマーカー
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US6239162B1 (en) 1999-05-17 2001-05-29 St. Elizabeth's Medical Center Method for treating depression
EP1410036A2 (de) 2001-01-19 2004-04-21 Mindsense Biosystems Ltd. Verfahren und zusammensetzung zur diagnose und behandlung von depression
EP1233075A3 (de) 2001-02-15 2003-01-08 Whitehead Institute For Biomedical Research BDNF Polymorphismus und Vereinigung mit doppelpoliger Geistesgestörtheit
EP1397484A4 (de) 2001-03-27 2005-05-25 Massachusetts Inst Technology Verfahren und produkte im zusammenhang mit fgf-dimerisierung
US20030166555A1 (en) 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
WO2002083877A1 (en) 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20030096264A1 (en) 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
US20030152972A1 (en) 2001-11-08 2003-08-14 Whitehead Institute For Biomedical Research Gene expression associated with psychiatric disorders
WO2003039490A2 (en) 2001-11-09 2003-05-15 Office Of Technology Licensing Stanford University Compositions and methods for diagnosing and treating mental disorders
US20040152107A1 (en) 2002-09-18 2004-08-05 C. Anthony Altar Gene signature of electroshock therapy and methods of use
WO2004047727A2 (en) 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosing and treating mood disorders
CA2504607A1 (en) * 2002-11-14 2004-05-27 Wyeth Methods and compositions for treating neurological disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20090105149A1 (en) 2003-08-07 2009-04-23 Enkam Pharmaceuticals A/S Compounds comprising lpa
US20050209181A1 (en) 2003-11-05 2005-09-22 Huda Akil Compositions and methods for diagnosing and treating mental disorders
JP2005312435A (ja) 2004-03-29 2005-11-10 Kazuhito Rokutan うつ病の評価方法
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
WO2009059316A1 (en) 2007-11-02 2009-05-07 The Board Of Trustees Of The Leland Stanford Junior University Fgf9-related methods for treating anxiety
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Also Published As

Publication number Publication date
EP2453024B1 (de) 2017-12-06
WO2006002262A2 (en) 2006-01-05
EP1766077B1 (de) 2012-03-28
EP2453024A2 (de) 2012-05-16
EP1766077A2 (de) 2007-03-28
US9486499B2 (en) 2016-11-08
EP2453024A3 (de) 2012-08-15
DK2453024T3 (en) 2018-02-12
EP1766077A4 (de) 2008-02-13
US8415298B2 (en) 2013-04-09
ES2660765T3 (es) 2018-03-26
AU2005258161A1 (en) 2006-01-05
US9957568B2 (en) 2018-05-01
WO2006002262A3 (en) 2007-06-14
US20140073568A1 (en) 2014-03-13
DK1766077T3 (da) 2012-07-16
US20060051786A1 (en) 2006-03-09
CA2571243A1 (en) 2006-01-05
US20170211144A1 (en) 2017-07-27
AU2005258161B2 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
ATE551432T1 (de) Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
BRPI0607307A2 (pt) compostos e composições como inibidores de proteìna cinase
ATE551350T1 (de) Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
HUE044182T2 (hu) Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
SG10201606441SA (en) Improved modalities for the treatment of degenerative diseases of the retina
EP1778341A4 (de) Dynamische nervenstimulierung zur behandlung von erkrankungen
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
ATE427759T1 (de) Behandlung von fettsucht und verbundenen erkrankungen
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
GB0425625D0 (en) Treatment of disease
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
WO2008125902A8 (en) Peripheral and neural inflammatory crosstalk
TW200735868A (en) Compositions and methods for treating CNS disorders
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
ATE511401T1 (de) Kombinierte gentherapie zur behandlung makroskopischer glioma
WO2006135694A3 (en) Uii-modulating compounds and their use